Joseph C.W. Tham, André Do, Jason Fridfinnson et al.
preprint
Intravenous (IV) ketamine has been shown to have rapid antidepressant effects in individuals with treatment-resistant depression (TRD). This treatment protocol describes a clinical method for use of subcutaneous (SC) and intramuscular (IM) racemic ketamine in individuals with TRD, developed by a team at the University of British Columbia (UBC), UBC Hospital, and Vancouver General Hospital. The...
Soukaina Es-Safi, Céline Bourcier-Lucas, Erika Abrial et al.
preprint
ABSTRACT Ketamine at subanaesthetic dose is known as a fast-acting antidepressant (AD), able to facilitate synaptic plasticity in the medial prefrontal cortex (mPFC) or the hippocampus. However, its influence on the serotonergic (5-HT) system is more confusing as it loses its behavioral effects in 5-HT-depleted animals, but does not modify 5-HT neuron function. We hypothesized that this...
Wanpeng Cui, Chen Shen, Wen-Cheng Xiong et al.
preprint
Summary Ketamine is a fast-acting, long-lasting novel antidepressant. However, underpinning intracellular mechanisms remain unclear. We conducted an unbiased screening for genes that were less expressed in the prefrontal cortex (PFC) of mice that did not display antidepression-like effects to ketamine. GO analysis implicated endoplasmic reticulum and protein folding; in particular, GRP78, a...
Yosra M. Magdy, Sherif A. Kamar, Hoda A. Fansa et al.
preprint
Abstract Mitochondrial dysfunction and oxidative stress may contribute to schizophrenia. Negative symptoms and cognitive dysfunction in individuals with schizophrenia are resistant to antipsychotic medications, but physical exercise is an effective treatment. Beneficial effects of exercise involve the release of irisin from skeletal muscle by activating mitochondrial peroxisome...
Keerati Pattanaseri, Juthawadee Lortrakul, Kankamol Jaisin et al.
preprint
Abstract Background: Studies have confirmed the rapid antidepressant action of ketamine in depressive episodes. Nevertheless, a standardized procedure for the delivery of ketamine infusion in individuals suffering from treatment-resistant depression, particularly in terms of infusion frequency and total dosage, remains undetermined. In addition, an efficacious ketamine regimen for persistent...
Paul Glue, Colleen Loo, Johnson Fam et al.
preprint
Abstract Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major depression (TRD). The safety and tolerability of racemic ketamine may be improved if given orally, as an extended release tablet (R-107), compared with other routes of administration. In this phase 2 multicentre clinical trial, adult patients with TRD and Montgomery-Asberg Depression Rating...
Shurong Li, Zhifang Zhuo, Renwei Li et al.
preprint
Abstract Background Postpartum depression (PPD) after cesarean delivery is a common complication. Esketamine's effects on PPD in women undergoing cesarean section remain contradictory, despite ketamine's prophylactic effects. This study evaluated the effect of esketamine as an adjunct to patient-controlled intravenous analgesia (PCIA) to prevent PPD in women undergoing caesarean section....
Shixia Xu, Jiaojiao Yang, Jing Li et al.
preprint
Abstract Background Postpartum depression (PPD) is a common mental disease in postpartum women, which has received more and more attention in society. Ketamine has been confirmed for its rapid antidepressant effect in women with PPD. We speculate that esketamine, an enantiomer of ketamine, pretreatment during cesarean can also reduce the incidence of PPD. Methods All the parturients enrolled in...
Michael Alvear
preprint
Ketamine has emerged as a plausible rapid-acting treatment for post-traumatic stress disorder (PTSD), but the clinical literature is unusually easy to overstate because a small number of randomized trials are repeatedly represented across reviews, several publications reuse the same cohorts, and treatment studies are sometimes mixed with PTSD-prevention studies conducted around acute trauma....
Vivian W. L. Tsang, Brendan Tao, Raimey Olthuis et al.
BACKGROUND Positive feedback from a mental health treatment program that uses treatment adjuncts inspired researchers to assess the potential role of the Apollo Neuro device in mental health outcomes. OBJECTIVE To assess the impact of the Apollo Neuro device on anxiety levels in a ketamine-assisted therapy treatment program, comparing those using the device with those not using the device....